325 related articles for article (PubMed ID: 25323474)
1. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 radioembolization is a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases: further evidence in support of a new treatment paradigm.
Hickey R; Lewandowski R; Salem R
Ann Surg Oncol; 2015 Mar; 22(3):706-7. PubMed ID: 25358665
[No Abstract] [Full Text] [Related]
6. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
Saxena A; Bester L; Shan L; Perera M; Gibbs P; Meteling B; Morris DL
J Cancer Res Clin Oncol; 2014 Apr; 140(4):537-47. PubMed ID: 24318568
[TBL] [Abstract][Full Text] [Related]
7. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
9. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
Saxena A; Bester L; Chua TC; Chu FC; Morris DL
Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
[TBL] [Abstract][Full Text] [Related]
11. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.
Saxena A; Chua TC; Bester L; Kokandi A; Morris DL
Ann Surg; 2010 May; 251(5):910-6. PubMed ID: 20395859
[TBL] [Abstract][Full Text] [Related]
13. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
Klingenstein A; Haug AR; Zech CJ; Schaller UC
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
16. Radioembolization in patients with hepatic metastases from breast cancer.
Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK
J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
[TBL] [Abstract][Full Text] [Related]
17. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.
Janowski E; Timofeeva O; Chasovskikh S; Goldberg M; Kim A; Banovac F; Pang D; Dritschilo A; Unger K
Oncol Rep; 2017 Jan; 37(1):57-65. PubMed ID: 28004119
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
[TBL] [Abstract][Full Text] [Related]
19. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Kousik V; Promila P; Verma R; Gupta A
Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
